A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors	Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease	Recruiting	Phase 1	2025-12-11		NCT07179679

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	32

14 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Affiliated Hospital of North Sichuan Medical College	Nanchong	China	13
Chongqing University Cancer Hospital	Chongqing	China	54
Guangdong Provincial People's Hospital	Guangzhou	China	6
Heze Municipal Hospital	Heze	China	2
Jiangsu Province Hospital	Nanjing	China	89
Nanchang University First Affiliated Hospital	Nanchang	China	2
Nanfang Hospital, Southern Medical University	Guangzhou	China	83
Nanjing Drum Tower Hospital	Nanjing	China	52
North China University of Science and Technology Affiliated Hospital	Tangshan	China	7
The Affiliated Hospital of Chengde Medical College	Chengde	China	2
The First Affiliated Hospital of Xi'an Jiaotong University	Xi'an	China	61
The Second Affiliated Hospital of Soochow University	Suzhou	China	8
Tianjin People's Hospital	Tianjin	China	2
Zhongshan Hospital of Fudan University	Shanghai	China	4